Alnylam Pharmaceuticals' Amortization of Deferred Charges rose 27.95% to $13.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $45.2 million, marking a year-over-year increase of 4.98%. This contributed to the annual value of $43.0 million for FY2023, which is 4.61% up from last year.
Latest data reveals that Alnylam Pharmaceuticals reported Amortization of Deferred Charges of $43.0 million as of FY2023, which was up 4.61% from $41.1 million recorded in FY2022.
Over the past 5 years, Alnylam Pharmaceuticals' Amortization of Deferred Charges peaked at $43.0 million during FY2023, and registered a low of $37.2 million during FY2019.
For the 3-year period, Alnylam Pharmaceuticals' Amortization of Deferred Charges averaged around $42.1 million, with its median value being $42.1 million (2021).
As far as peak fluctuations go, Alnylam Pharmaceuticals' Amortization of Deferred Charges climbed by 6.64% in 2020, and later dropped by 2.48% in 2022.
Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Amortization of Deferred Charges stood at $37.2 million in 2019, then climbed by 6.64% to $39.7 million in 2020, then climbed by 6.21% to $42.1 million in 2021, then decreased by 2.48% to $41.1 million in 2022, then grew by 4.61% to $43.0 million in 2023.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value